908 Devices Inc. (NASDAQ:MASS) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its position in 908 Devices Inc. (NASDAQ:MASS) by 88.3% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 245,176 shares of the company’s stock after buying an additional 114,987 shares during the quarter. Dimensional Fund Advisors LP’s holdings in 908 Devices were worth $1,263,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of MASS. ClariVest Asset Management LLC acquired a new position in 908 Devices in the 2nd quarter valued at $668,000. AWM Investment Company Inc. increased its stake in 908 Devices by 2.3% in the 1st quarter. AWM Investment Company Inc. now owns 668,526 shares of the company’s stock valued at $5,047,000 after buying an additional 15,058 shares during the period. State Board of Administration of Florida Retirement System acquired a new position in 908 Devices in the 1st quarter valued at $80,000. GAMMA Investing LLC acquired a new position in 908 Devices in the 2nd quarter valued at $48,000. Finally, Vanguard Group Inc. increased its stake in 908 Devices by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 1,751,102 shares of the company’s stock valued at $13,221,000 after buying an additional 6,772 shares during the period. 88.06% of the stock is owned by institutional investors and hedge funds.

908 Devices Stock Performance

Shares of MASS opened at $3.47 on Friday. The stock has a market capitalization of $120.27 million, a P/E ratio of -3.02 and a beta of 0.97. The company’s fifty day moving average is $3.83 and its two-hundred day moving average is $5.16. 908 Devices Inc. has a 1 year low of $3.24 and a 1 year high of $12.51.

908 Devices (NASDAQ:MASS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.02. 908 Devices had a negative net margin of 72.10% and a negative return on equity of 22.47%. The business had revenue of $14.05 million for the quarter, compared to analysts’ expectations of $13.69 million. Sell-side analysts predict that 908 Devices Inc. will post -1.21 EPS for the current year.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.